PCSK9 Inhibitor Eligibility Checker

Determines eligibility for PCSK9 inhibitor therapy (evolocumab, alirocumab). Indicated for very high-risk patients with clinical ASCVD and LDL-C ≥70 mg/dL on maximally tolerated statin therapy (with or without ezetimibe). Also indicated for heterozygous or homozygous familial hypercholesterolemia. PCSK9 inhibitors reduce LDL-C by 50–65% and reduce MACE by 15–20%.

Weight
Height
Clinical Guidance

BMI is a screening measure of body size, not a direct measure of body fat. The standard WHO categories are underweight (<18.5), normal (18.5–24.9), overweight (25–29.9), and obese (≥30).

BMI can overestimate body fat in athletes with high muscle mass and underestimate it in older adults with low muscle mass. Interpret it alongside waist circumference and clinical context rather than as a standalone diagnosis.

⚕ Clinical Disclaimer: These calculators are for educational and reference purposes only. Always verify results with qualified clinical judgment and current clinical guidelines. Do not use as a sole basis for medical decisions.
Advertisement

How to Use

Enter the values for the scenario you are assessing. Determines eligibility for PCSK9 inhibitor therapy (evolocumab, alirocumab). Indicated for very high-risk patients with clinical ASCVD and LDL-C ≥70 mg/dL on maximally tolerated statin therapy (with or without ezetimibe). Also indicated for heterozygous or homozygous familial hypercholesterolemia. PCSK9 inhibitors reduce LDL-C by 50–65% and reduce MACE by 15–20%. Use the pcsk9 eligibility result to inform your calculation.

Related Calculators

Statin Intensity

Medical

Lp(a) CV Risk

Medical

Non-HDL Target

Medical

Frequently Asked Questions